Sunday, April 17, 2011

DRUG AND DRUG TARGET

DRUGS AND DRUG TARGETS


What is a drug target? And how many such targets are there? Here, we consider the nature of drug targets, and by classifying known drug substances on the basis of the discussed principles we provide an estimation of the total number of current drug targets.
Estimations of the total number of drug targets are presently dominated by analyses of the human genome, which are limited for various reasons, including the inability to infer the existence of splice variants or interactions between the encoded proteins from gene sequences alone, and the fact that the function of most of the DNA in the genome remains unclear. In 1997, when 100,000 protein-coding sequences were hypothesized to exist in the human genome, Drews and Ryser estimated the number of molecular targets 'hit' by all marketed drug substances to be only 482 .In 2002, after the sequencing of the human genome, others arrived at 8,000 targets of pharmacological interest, of which nearly 5,000 could be potentially hit by traditional drug substances, nearly 2,400 by antibodies and 800 by protein pharmaceuticals. And on the basis of ligand-binding studies, 399 molecular targets were identified belonging to 130 protein families, and 3,000 targets for small-molecule drugs were predicted to exist by extrapolations from the number of currently identified such targets in the human genome.
In summary, current target counts are of the order of 102, whereas estimations of the number of potential drug targets are an order of magnitude higher. In this paper, we consider the nature of drug targets, and use a classification based on this consideration, and a list of approved drug substances to estimate the number of known drug targets, in the following categories:
Type
Activity of drug
Drug examples
Oxidoreductases
Aldehyde dehydrogenase
Inhibitor
Disulfiram
Monoamine oxidases (MAOs)
MAO-A inhibitor
Tranylcypromine, moclobemide

MAO-B inhibitor
Tranylcypromine
Cyclooxygenases (COXs)
COX1 inhibitor
Acetylsalicylic acid, profens, acetaminophen and dipyrone (as arachidonylamides)

COX2 inhibitor
Acetylsalicylic acid, profens, acetaminophen and dipyrone (as arachidonylamides)
Vitamin K epoxide reductase
Inhibitor
Warfarin, phenprocoumon
Aromatase
Inhibitor
Exemestane
Lanosterol demethylase (fungal)
Inhibitor
Azole antifungals
Lipoxygenases
Inhibitor
Mesalazine

5-lipoxygenase inhibitor
Zileuton
Thyroidal peroxidase
Inhibitor
Thiouracils
Iodothyronine-5' deiodinase
Inhibitor
Propylthiouracil
Inosine monophosphate dehydrogenase
Inhibitor
Mycophenolate mofetil
HMG-CoA reductase
Inhibitor
Statins
5 -Testosterone reductase
Inhibitor
Finasteride, dutasteride
Dihydrofolate reductase (bacterial)
Inhibitor
Trimethoprim
Dihydrofolate reductase (human)
Inhibitor
Methotrexate, pemetrexed
Dihydrofolate reductase (parasitic)
Inhibitor
Proguanil
Dihydroorotate reductase
Inhibitor
Leflunomide
Enoyl reductase (mycobacterial)
Inhibitor
Isoniazid
Squalene epoxidase (fungal)
Inhibitor
Terbinafin
14 reductase (fungal)
Inhibitor
Amorolfin
Xanthine oxidase
Inhibitor
Allopurinol
4-Hydroxyphenylpyruvate dioxygenase
Inhibitor
Nitisinone
Ribonucleoside diphosphate reductase
Inhibitor
Hydroxycarbamide
Transferases
Protein kinase C
Inhibitor
Miltefosine
Bacterial peptidyl transferase
Inhibitor
Chloramphenicol
Catecholamine-O-methyltransferase
Inhibitor
Entacapone
RNA polymerase (bacterial)
Inhibitor
Ansamycins
Reverse transcriptases (viral)
Competitive inhibitors
Zidovudine

Allosteric inhibitors
Efavirenz
DNA polymerases
Inhibitor
Acyclovir, suramin
GABA transaminase
Inhibitor
Valproic acid vigabatrin
Tyrosine kinases
PDGFR/ABL/KIT inhibitor
Imatinib

EGFR inhibitor
Erlotinib

VEGFR2/PDGFR /KIT/FLT3
Sunitinib

VEGFR2/PDGFR /RAF
Sorafenib
Glycinamide ribonucleotide formyl transferase
Inhibitor
Pemetrexed
Phosphoenolpyruvate transferase (MurA, bacterial)
Inhibitor
Fosfomycin
Human cytosolic branched-chain aminotransferase (hBCATc)
Inhibitor
Gabapentin
Hydrolases (proteases)
Aspartyl proteases (viral)
HIV protease inhibitor
Saquinavir, indinavir
Hydrolases (serine proteases)
Unspecific
Unspecific inhibitors
Aprotinine
Bacterial serine protease
Direct inhibitor
-lactams
Bacterial serine protease
Indirect inhibitor
Glycopeptides
Bacterial lactamases
Direct inhibitor
Sulbactam
Human antithrombin
Activator
Heparins
Human plasminogen
Activator
Streptokinase
Human coagulation factor
Activator
Factor IX complex, Factor VIII
Human factor Xa
Inhibitor
Fondaparinux
Hydrolases (metalloproteases)
Human ACE
Inhibitor
Captopril
Human HRD
Inhibitor
Cilastatin
Human carboxypeptidase A (Zn)
Inhibitor
Penicillamine
Human enkephalinase
Inhibitor
Racecadotril
Hydrolases (other)
26S proteasome
Inhibitor
Bortezomib
Esterases
AChE inhibitor
Physostigmine

AChE reactivators
Obidoxime

PDE inhibitor
Caffeine

PDE3 inhibitor
Amrinon, milrinone

PDE4 inhibitor
Papaverine

PDE5 inhibitor
Sildenafil

HDAC inhibitor
Valproic acid

HDAC3/HDAC7 inhibitor
Carbamezepine
Glycosidases (viral)
-glycosidase inhibitor
Zanamivir, oseltamivir
Glycosidases (human)
-glycosidase inhibitor
Acarbose
Lipases
Gastrointestinal lipases inhibitor
Orlistat
Phosphatases
Calcineurin inhibitor
Cyclosporin

Inositol polyphosphate phosphatase inhibitor
Lithium ions
GTPases
Rac1 inhibitor
6-Thio-GTP (azathioprine metabolite)
Phosphorylases
Bacterial C55-lipid phosphate dephosphorylase inhibitor
Bacitracin
Lyases
DOPA decarboxylase
Inhibitor
Carbidopa
Carbonic anhydrase
Inhibitor
Acetazolamide
Histidine decarboxylase
Inhibitor
Tritoqualine
Ornithine decarboxylase
Inhibitor
Eflornithine
Soluble guanylyl cyclase
Activator
Nitric acid esters, molsidomine
Isomerases
Alanine racemase
Inhibitor
D-Cycloserine
DNA gyrases (bacterial)
Inhibitor
Fluoroquinolones
Topoisomerases
Topoisomerase I inhibitor
Irinotecan

Topoisomerase II inhibitor
Etoposide
8,7 isomerase (fungal)
Inhibitor
Amorolfin
Ligases (also known as synthases)
Dihydropteroate synthase
Inhibitor
Sulphonamides
Thymidylate synthase (fungal and human)
Inhibitor
Fluorouracil
Thymidylate synthase (human)
Inhibitor
Methotrexate, pemetrexed
Phosphofructokinase
Inhibitor
Antimony compounds
mTOR
Inhibitor
Rapamycin
Haem polymerase (Plasmodium)
Inhibitor
Quinoline antimalarials
1,3- -D-glucansynthase (fungi)
Inhibitor
Caspofungin
Glucosylceramide synthase
Inhibitor
Miglustat
TABLE 2 | Receptors
Type
Activity of drug
Drug examples
Direct ligand-gated ion channel receptors
GABAA receptors
Barbiturate binding site agonists
Barbiturate

Benzodiazepine binding site agonists
Benzodiazepines

Benzodiazepine binding site antagonists
Flumazenil
Acetylcholine receptors
Nicotinic receptor agonists
Pyrantel (of Angiostrongylus), levamisole

Nicotinic receptor stabilizing antagonists
Alcuronium

Nicotinic receptor depolarizing antagonists
Suxamethonium

Nicotinic receptor allosteric modulators
Galantamine
Glutamate receptors (ionotropic)
NMDA subtype antagonists
Memantine

NMDA subtype expression modulators
Acamprosate

NMDA subtype phencyclidine binding site antagonists
Ketamine
G-protein-coupled receptors
Acetylcholine receptors
Muscarinic receptor agonists
Pilocarpine

Muscarinic receptor antagonists
Tropane derivatives

Muscarinic receptor M3 antagonists
Darifenacine
Adenosine receptors
Agonists
Adenosine

Adenosine A1 receptor agonists
Lignans from valerian

Adenosine A1receptor antagonists
Caffeine, theophylline

Adenosine A2A receptor antagonists
Caffeine, theophylline
Adrenoceptors
Agonists
Adrenaline, noradrenaline, ephedrine

1- and 2-receptors agonists
Xylometazoline

1-receptor antagonists
Ergotamine

2-receptor, central agonists
Methyldopa (as methylnoradrenaline)

-adrenoceptor antagonists
Isoprenaline

1-receptor antagonists
Propranolol, atenolol

2-receptor agonists
Salbutamol

2-receptor antagonists
Propranolol
Angiotensin receptors
AT1-receptors antagonists
Sartans
Calcium-sensing receptor
Agonists
Strontium ions

Allosteric activators
Cinacalcet
Cannabinoid receptors
CB1 - and CB2-receptors agonists
Dronabinol
Cysteinyl-leukotriene receptors
Antagonists
Montelukast
Dopamine receptors166
Dopamine receptor subtype direct agonists
Dopamine, levodopa

D2, D3 and D4 agonists
Apomorphine

D2, D3 and D4 antagonists
Chlorpromazine, fluphenazine, haloperidol, metoclopramide, ziprasidone
Endothelin receptors (ETA, ETB)
Antagonists
Bosentan
GABAB receptors
Agonists
Baclofen
Glucagon receptors
Agonists
Glucagon
Glucagon-like peptide-1 receptor
Agonists
Exenatide
Histamine receptors
H1-antagonists
Diphenhydramine

H2-antagonists
Cimetidine
Opioid receptors173, 174
-opioid agonists
Morphine, buprenorphine

-, - and -opioid antagonists
Naltrexone

-opioid antagonists
Buprenorphine
Neurokinin receptors
NK1 receptor antagonists
Aprepitant
Prostanoid receptors
Agonists
Misoprostol, sulprostone, iloprost
Prostamide receptors
Agonists
Bimatoprost
Purinergic receptors
P2Y12 antagonists
Clopidogrel
Serotonin receptors
Subtype-specific (partial) agonists
Ergometrine, ergotamine

5-HT1A partial agonists
Buspirone

5-HT1B/1D agonists
Triptans

5-HT2A antagonists
Quetiapine, ziprasidone

5-HT3 antagonists
Granisetron

5-HT4 partial agonists
Tegaserode
Vasopressin receptors184
Agonists
Vasopressin

V1 agonists
Terlipressin

V2 agonists
Desmopressin

OT agonists
Oxytocin

OT antagonists
Atosiban
Cytokine receptors
Class I cytokine receptors
Growth hormone receptor antagonists
Pegvisomant

Erythropoietin receptor agonists
Erythropoietin

Granulocyte colony stimulating factor agonists
Filgrastim

Granulocyte-macrophage colony stimulating factor agonists
Molgramostim

Interleukin-1 receptor antagonists
Anakinra

Interleukin-2 receptor agonists
Aldesleukin
TNF receptors
Mimetics (soluble)
Etanercept
Integrin receptors
Glycoprotein IIb/IIIa receptor
Antagonists
Tirofiban
Receptors associated with a tyrosine kinase
Insulin receptor
Direct agonists
Insulin
Insulin receptor
Sensitizers
Biguanides
Nuclear receptors (steroid hormone receptors)
Mineralocorticoid receptor196
Agonists
Aldosterone

Antagonists
Spironolactone
Glucocorticoid receptor
Agonists
Glucocorticoids
Progesterone receptor
Agonists
Gestagens
Oestrogen receptor199
Agonists
Oestrogens

(Partial) antagonists
Clomifene

Antagonists
Fulvestrant

Modulators
Tamoxifen, raloxifene

Androgen receptor201, 202 Agonists
Testosterone

Antagonists
Cyproterone acetate
Vitamin D receptor205, 206
Agonists
Retinoids
ACTH receptor agonists
Agonists
Tetracosactide (also known as cosyntropin)
Nuclear receptors (other)

Retinoic acid receptors RAR agonists
Isotretinoin

RAR agonists
Adapalene, isotretinoin

RAR agonists
Adapalene, isotretinoin
Peroxisome proliferator-activated receptor (PPAR)
PPAR agonists
Fibrates

PPAR agonists
Glitazones
Thyroid hormone receptors
Agonists
L-Thyroxine
Download file
If the slide opens in your browser, select "File > Save As" to save
TABLE 3 | Ion channels
|
Type
Activity of drug
Drug examples
Voltage-gated Ca2+ channels
General
Inhibitor
Oxcarbazepine
In Schistosoma sp.
Inhibitor
Praziquantel
L-type channels
Inhibitor
Dihydropyridines, diltiazem, lercanidipine, pregabalin, verapamil
T-type channels
Inhibitor
Succinimides
K+ channels225
Epithelial K+ channels
Opener Inhibitor
Diazoxide, minoxidilNateglinide, sulphonylureas
Voltage-gated K+ channels
Inhibitor
Amiodarone
Na+ channels
Epithelial Na+ channels (ENaC)231
Inhibitor
Amiloride, bupivacaine, lidocaine, procainamide, quinidine
Voltage-gated Na+ channels
Inhibitor
Carbamazepine, flecainide, lamotrigine, phenytoin, propafenone, topiramate, valproic acid,  
Ryanodine-inositol 1,4,5-triphosphate receptor Ca2+ channel (RIR-CaC) family
Ryanodine receptors
Inhibitor
Dantrolene
Transient receptor potential Ca2+ channel (TRP-CC) family
TRPV1 receptors
Inhibitor
Acetaminophen (as arachidonylamide)
Cl- channels243
Cl-channel
Inhibitor (mast cells) Opener (parasites)
Cromolyn sodium Ivermectin
·        
TABLE 4 | Transport proteins (uniporters, symporters and antiporters)
Type
Activity of drug
Drug examples
Cation-chloride cotransporter (CCC) family247
Thiazide-sensitive NaCl symporter, human inhibitor
Thiazide diuretics

Bumetanide-sensitive NaCl/KCl symporters, human inhibitor
Furosemide
Na+/H+ antiporters
Inhibitor
Amiloride, triamterene
Proton pumps
Ca2+-dependent ATPase (PfATP6; Plasmodia) inhibitor
Artemisinin and derivatives
H+/K+-ATPase
Inhibitor
Omeprazole
Na+/K+ ATPase
Inhibitor
Cardiac glycosides
Eukaryotic (putative) sterol transporter (EST) family
Niemann-Pick C1 like 1 (NPC1L1) protein inhibitor
Ezetimibe
Neurotransmitter/Na+ symporter (NSS) family257, 258
Serotonin/Na+ symporter inhibitor
Cocaine, tricyclic antidepressants, paroxetine

Noradrenaline/Na+ symporter inhibitor
Bupropion, venlafaxine

Dopamine/Na+ symporter inhibitor
Tricyclic antidepressants, cocaine, amphetamines

Vesicular monoamine transporter inhibitor
Reserpine

|
TABLE 5 | DNA/RNA and the ribosome

Target
Activity of drug
Example drugs
Nucleic acids
DNA and RNA265
Alkylation
Chlorambucil, cyclophosphamide, dacarbazine

Complexation
Cisplatin

Intercalation
Doxorubicin

Oxidative degradation
Bleomycin

Strand breaks
Nitroimidazoles
RNA
Interaction with 16S-rRNA
Aminoglycoside antiinfectives

Interaction with 23S-rRNA
Macrolide antiinfectives

23S-rRNA/tRNA/2-polypeptide complex
Oxazolidinone antiinfectives
Spindle
Inhibition of development
Vinca alkaloids

Inhibition of desaggregation
Taxanes
Inhibition of mitosis
Colchicine
Ribosome
30S subunit (bacterial)
Inhibitors
Tetracyclines
50S subunit (bacterial)
Inhibitors
Lincosamides, quinupristin– dalfopristin282, 283
TABLE 6 | Targets of monoclonal antibodies
|
Target
Agent
Vascular endothelial growth factor
Bevacizumab
Lymphocyte function-associated antigen 1
Efalizumab
Epidermal growth factor receptor
Cetuximab
Human epidermal growth factor receptor 2
Trastuzumab
Immunoglobulin E (IgE)
Omalizumab
CD-3
Muromonab-CD3
CD-20
Rituximab, ibritumomab tiuxetan, 131I-tositumomab
CD-33
Gemtuzumab
CD-52
Alemtuzumab
F protein of RSV subtypes A and B
Palivizumab
CD-25
Basiliximab, daclizumab
Tumour-necrosis factor-
Adalimumab, infliximab
Glycoprotein IIb/IIIa receptor
Abciximab
4-Integrin subunit
Natalizumab
·        
TABLE 7 | Various physicochemical mechanisms
|
Mechanism
Agent
Ion exchange
Fluoride
Acid binding
Magnesium hydroxide, aluminium hydroxide
Adsorptive
Charcoal, colestyramine
Adstringent
Bismuth compounds
Surface-active
Simeticone, chlorhexidine, chloroxylene
Surface-active on cell membranes
Coal tar
Surface-active from fungi
Nystatin, amphotericin B
Mucosal irritation
Anthrones, anthraquinones
Osmotically active
Lactulose, dextran 70, polygeline, glucose, electrolyte solutions, mannitol
Water binding
Urea, ethanol
UV absorbant
4-Aminobenzoic acid derivatives
Reflective
Zinc oxide, titanium dioxide
Oxidative
Tannines, polyphenoles, dithranol, polyvidon iodide, silver nitrate, hypochlorite, permanganate, benzoylperoxide, nitroimidazoles, nitrofuranes, temoporfin (mainly via singlet oxygen, cytostatic drug), verteporfin (mainly via singlet oxygen, ophthalmic drug)
Reduce disulphide bridges
D-Penicillamine, N-acetyl-cysteine
Complexing agents
Al3+, arsenic compounds
Salt formation
Sevelamer
Modification of tertiary structure
Enfuvirtide (from HIV glycoprotein 41)

2 comments:


  1. I was diagnosed as HEPATITIS B carrier in 2013 with fibrosis of the

    liver already present. I started on antiviral medications which

    reduced the viral load initially. After a couple of years the virus

    became resistant. I started on HEPATITIS B Herbal treatment from

    ULTIMATE LIFE CLINIC (www.ultimatelifeclinic. com) in March, 2020. Their

    treatment totally reversed the virus. I did another blood test after

    the 6 months long treatment and tested negative to the virus. Amazing

    treatment! This treatment is a breakthrough for all HBV carriers.

    ReplyDelete